An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Trial Profile

An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Mobilised-peripheral-blood-cells (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions; Proof of concept
  • Sponsors Cellect Biotechnology
  • Most Recent Events

    • 27 Mar 2017 According to a Cellect Biotechnology media release, the first stem cell transplant procedure has been successfully performed using its ApoGraft technology in this trial.
    • 23 Mar 2017 According to a Cellect Biotechnology media release, the first patient has been treated in this trial.
    • 02 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top